The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer

Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.

EP: 1.Case Presentation: A 67-Year-Old-Man with Metastatic Prostate Cancer

EP: 2.Available Systemic Therapy Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy

EP: 3.Factors for Consideration When Selecting Treatments for Patients with mCRPC

Now Viewing

EP: 4.The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer

EP: 5.Unmet Needs, Future Directions, and Clinical Pearls in mCRPC

Related Videos

Related Content

Advertisement

March 22nd 2025

Data reinforce isodose MHFRT as standard of care radiotherapy regimen

Hannah Clarke

“These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, MD.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

March 20th 2025

Trial launches of CBP/p300 inhibitor in mCRPC

Hannah Clarke

Pocenbrodib is an oral, small molecule designed to inhibit the proteins CREBBP/EP300, which activate genes that promote cancer cell growth and proliferation.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

March 17th 2025

Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer

Michael R. Folkert, MD, PhD Benjamin P. Saylor

"4 years following radiation therapy, there is a 25% lower hazard of bowel disorders and a 46% lower hazard of related procedures [in patients who received a spacer],” says Michael R. Folkert, MD, PhD.

March 13th 2025

Radioligand therapy shows promising safety in patients with mCRPC

Hannah Clarke

The mean absorbed radiation dose to tumors was 8.9 Gy/GBq, compared with 0.27 Gy/GBq in the kidneys and 0.13 Gy/GBq in the salivary glands.

Related Content

Advertisement

March 22nd 2025

Data reinforce isodose MHFRT as standard of care radiotherapy regimen

Hannah Clarke

“These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, MD.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

March 20th 2025

Trial launches of CBP/p300 inhibitor in mCRPC

Hannah Clarke

Pocenbrodib is an oral, small molecule designed to inhibit the proteins CREBBP/EP300, which activate genes that promote cancer cell growth and proliferation.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

March 17th 2025

Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer

Michael R. Folkert, MD, PhD Benjamin P. Saylor

"4 years following radiation therapy, there is a 25% lower hazard of bowel disorders and a 46% lower hazard of related procedures [in patients who received a spacer],” says Michael R. Folkert, MD, PhD.

March 13th 2025

Radioligand therapy shows promising safety in patients with mCRPC

Hannah Clarke

The mean absorbed radiation dose to tumors was 8.9 Gy/GBq, compared with 0.27 Gy/GBq in the kidneys and 0.13 Gy/GBq in the salivary glands.